載入...
Safety and Immunogenicity of a Novel Intranasal Influenza Vaccine (NasoVAX): A Phase 2 Randomized, Controlled Trial
Annual influenza vaccination greatly reduces morbidity and mortality, but effectiveness remains sub-optimal. Weaknesses of current vaccines include low effectiveness against mismatched strains, lack of mucosal and other effective tissue-resident immune responses, weak cellular immune responses, and...
Na minha lista:
| 發表在: | Vaccines (Basel) |
|---|---|
| Main Authors: | , , , , , , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
MDPI
2021
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8000446/ https://ncbi.nlm.nih.gov/pubmed/33807649 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/vaccines9030224 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|